New biomarkers of acute kidney injury

被引:184
作者
Parikh, Chirag R. [1 ,2 ]
Devarajan, Prasad [3 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06510 USA
[2] Vet Adm Med Ctr, New Haven, CT USA
[3] Univ Cincinnati, Childrens Hosp, Div Nephrol & Hypertens, Med Ctr, Cincinnati, OH USA
关键词
acute renal failure; acute kidney injury; neutrophil gelatinase-associated lipocalin; cystatin C; interleukin; 18; kidney injury molecule-1; biomarker panel;
D O I
10.1097/CCM.0b013e318168c652
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Acute kidney injury (AKI) represents a major clinical problem, with rising incidence and high mortality rate. The lack of early biomarkers has resulted in a delay in initiating therapies. Fortunately, the tools of modern science have revealed promising novel biomarkers for AKI, with potentially high sensitivity and specificity. These include a plasma panel (neutrophil gelatinase-associated lipocalin and cystatin C) and a urine panel (neutrophil gelatinase-associated lipocalin, interleukin 18, and kidney injury molecule-1). Because they represent sequential biomarkers, it is likely that the AKI panels will be useful for timing the initial insult and assessing the duration of AKI (analogous to the cardiac panel for evaluating chest pain) and for predicting overall prognosis with respect to dialysis requirement and mortality. It is also likely that the AKI panels will help distinguish between the various types and pathogeneses of AKI. It will be important in future studies to validate the sensitivity and specificity of these biomarker panels in clinical samples from large cohorts and from multiple clinical situations. Such studies will be markedly facilitated by multidisciplinary participation of various specialties (intensivists, cardiologists, surgeons) in AKI clinical studies and by the availability of commercial tools for the reliable and reproducible measurement of biomarkers across different laboratories.
引用
收藏
页码:S159 / S165
页数:7
相关论文
共 79 条
  • [1] A trial of thyroxine in acute renal failure
    Acker, CG
    Singh, AR
    Flick, RP
    Bernardini, J
    Greenberg, A
    Johnson, JP
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (01) : 293 - 298
  • [2] Åhlström A, 2004, CLIN NEPHROL, V62, P344
  • [3] Anaritide in acute tubular necrosis
    Allgren, RL
    Marbury, TC
    Rahman, SN
    Weisberg, LS
    Fenves, AZ
    Lafayette, RA
    Sweet, RM
    Genter, FC
    Kurnik, BRC
    Conger, JD
    Sayegh, MH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (12) : 828 - 834
  • [4] American Society of Nephrology, 2005, J Am Soc Nephrol, V16, P1886
  • [5] Molecular and structural consequences of early renal allograft injury
    Baboolal, K
    Jones, GA
    Janezic, A
    Griffiths, DR
    Jurewicz, WA
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (02) : 686 - 696
  • [6] Defining, quantifying, and classifying acute renal failure
    Bellomo, R
    [J]. CRITICAL CARE CLINICS, 2005, 21 (02) : 223 - +
  • [7] The epidemiology of acute renal failure: 1975 versus 2005
    Bellomo, Rinaldo
    [J]. CURRENT OPINION IN CRITICAL CARE, 2006, 12 (06) : 557 - 560
  • [8] Outcome and predictive factors of acute renal failure in the intensive care unit
    Bernieh, B
    Al Hakim, M
    Boobes, Y
    Siemkovics, E
    El Jack, H
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (06) : 1784 - 1787
  • [9] The epidemiology and outcome of acute renal failure and the impact on chronic kidney disease
    Block, Clay A.
    Schoolwerth, Anton C.
    [J]. SEMINARS IN DIALYSIS, 2006, 19 (06) : 450 - 454
  • [10] The incidence and risk of acute renal failure after cardiac surgery
    Bove, T
    Calabrò, MG
    Landoni, G
    Aletti, G
    Marino, G
    Crescenzi, G
    Rosica, C
    Zangrillo, A
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2004, 18 (04) : 442 - 445